

7–9, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Predoctoral Training in Primary Care.

Date and Time: May 13–16, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: May 13, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 13, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May 14–16, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Geriatric Training for Physicians, Dentists, and Behavioral and Mental Health Professionals.

Date and Time: May 13–16, 2002.

Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Open on: May 13, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 13, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May 14–16, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Academic Administrative Units in Primary Care.

Date and Time: May 20–23, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: May 20, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 20, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May 21–23, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Geriatric Academic Career Awards.

Date and Time: June 3–6, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: June 3, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: June 3, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); June 4–6, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Health Education and Training Centers.

Date and Time: June 10–13, 2002.

Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Open on: June 10, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: June 10, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); June 11–13, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Graduate Psychology Education Program.

Date and Time: July 29–August 1, 2002.

Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Open on: July 29, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: July 29, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); July 30–August 1, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: National Research Service Awards.

Date and Time: August 5–6, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: August 5, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: August 5, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); August 6, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Dated: March 1, 2002.

Jane M. Harrison,

Director, Division of Policy Review and Coordination.

[FR Doc. 02–5357 Filed 3–6–02; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Opportunity for a Cooperative Research and Development Agreement (CRADA) To Develop Live Attenuated Dengue Viruses for Use as Vaccines in Humans

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) is seeking Capability Statements from parties interested in entering into a Cooperative Research and Development Agreement (CRADA) on a project to develop live attenuated dengue viruses for use as vaccines to prevent dengue hemorrhagic fever and dengue shock syndrome in humans. This project is part of ongoing vaccine development activities in the Laboratory of Infectious Diseases (LID), Division of Intramural Research, NIAID.

DATES: Only written CRADA Capability Statements received by the NIAID on or before April 18, 2002, will be considered.

ADDRESSES: Capability Statements should be submitted to Dr. Michael R. Mowatt, Office of Technology Development, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Drive MSC 2137, Building 31, Room 3B62, Bethesda, MD 20892–2137; Tel: 301/496–2644, Fax: 301/402–7123; Electronic mail: mmowatt@nih.gov.

SUPPLEMENTARY INFORMATION: The CRADA will employ attenuated dengue virus strains (types 1 through 4) developed in LID using recombinant DNA methodologies to (1) identify and characterize the mutations responsible for attenuation, (2) engineer viral strains suitably attenuated for use as human vaccines, and (3) evaluate the attenuated viruses as live vaccines in animals, including rhesus monkeys, and humans. The Public Health Service (PHS) has filed patent applications both in the

U.S. and internationally related to these technologies.

The LID has extensive experience in evaluating the safety, immunogenicity and efficacy of various human viral pathogens and vaccines thereof both in experimental animals and human volunteers. The LID has identified two approaches to produce attenuated dengue virus vaccine candidates each incorporating a stable, clinically tested deletion mutation capable of attenuating dengue viruses for humans. In addition, a large set of additional attenuating mutations have been identified that will be available to further attenuate vaccine candidates that prove to be incompletely attenuated in human trials. The Collaborator in this endeavor is expected to commit several scientists off-site to support the activities defined by the CRADA Research Plan. These scientists, in collaboration with investigators in the LID, would coordinate the production and release testing of the candidate vaccines, generate monoclonal antibodies or other antibodies needed for production and characterization of clinical lots, and use molecular virologic techniques to generate attenuating mutations suitable for use in live vaccine candidates. The LID and Collaborator will identify the best candidate dengue virus attenuated derivatives for each of the four dengue virus serotypes to formulate a tetravalent vaccine. In addition, it is expected that the Collaborator will provide funds to supplement LID's research budget for the project and would make a major funding commitment to support the safety, immunogenicity and efficacy studies for candidate vaccines developed under the CRADA.

The capability statement must address, with specificity and providing appropriate examples, each of the following selection criteria: (1) The technical expertise of the Collaborator's Principal Investigator and laboratory group in molecular virology; (2) The number of personnel that the Collaborator plans to assign to this project; (3) Ability of Collaborator to manufacture experimental vaccine lots for parenteral administration under Good Manufacturing Practices (GMP) conditions and the number of lots that could be produced annually, (4) Access to a qualified bank of cells for vaccine manufacture, specifically Vero cells or DBS FRhL–2 cells, (5) Capability to manage regulatory affairs attendant to licensure by FDA and international regulatory bodies, and (6) Ability to provide adequate and sustained funding to support pre-clinical development at NIH and at collaborator's site and for the

requisite vaccine safety, immunogenicity, and efficacy studies in humans.

Dated: February 28, 2002.

Michael R. Mowatt,

Director, Office of Technology Development, NIAID.

[FR Doc. 02-5504 Filed 3-6-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel.

Date: March 15, 2002.

Time: 2 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: 6116 Executive Boulevard, Rockville, MD 20892. (Telephone Conference Call).

Contact Person: Raymond A. Petryshyn, PHD, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., 8th Fl., Room 8133, Bethesda, MD 20892. 301/594-1216.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 1, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-5493 Filed 3-6-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Research Resources Special Emphasis Panel Comparative Medicine.

Date: March 20, 2002.

Time: 1:00 PM to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Office of Review, National Center for Research Resources, 6705 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call).

Contact Person: Camille M. King, PHD, Scientific Review Administrator, Office of Review, National Center for Research Resources, National Institutes of Health, One Rockledge Centre, MSC 7965, 6705 Rockledge Drive, Suite 6018, Bethesda, MD 20892-7965. (301) 435-0810. kingc@ncrr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333; 93.371, Biomedical Technology; 93.389, Research Infrastructure, National Institutes of Health, HHS)

Dated: February 27, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-5496 Filed 3-6-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel.

Date: April 16, 2002.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn—Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Contact Person: Jon M. Ranhand, PhD, Scientist Review Administrator, Division of Scientific Review, National Institute of Child Health, and Human Development, NIH, 6100 Executive Blvd., Room 5E03, Bethesda, MD 20892. (301) 435-6884.

(Catalogue of Federal Domestic Assistance Program Nos. 93.209, Contraception and Infertility Loan Repayment Program; 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research, National Institutes of Health, HHS)

Dated: March 1, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02-5491 Filed 3-6-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the